Dr. Amyn Sayani is currently the Director, Medical Evidence at AstraZeneca Canada, where he is accountable for all real-world evidence, outcomes research studies, and externally sponsored research across multiple therapy areas. Amyn joined AstraZeneca in March 2021 after 20 years at GlaxoSmithKline and the last two years at a medical cannabis company as Vice President, R&D. Amyn has served in various roles of increasing responsibility across the drug development and commercialization continuum, including product development, regulatory and medical affairs, health economics and outcomes research, and real-world evidence, and market access. In his most recent role at GSK, Amyn led the development and implementation of GSK’s RWE strategy through broad partnerships across public, private and academic stakeholders. He has authored numerous publications and patents and has led numerous projects to optimize patient access to innovative medicines. Amyn is a pharmacist by training, and has a PhD in Pharmaceutical Sciences (Rutgers University), and a Masters of Science in Health Research Methodology (McMaster University, Ontario).